Checkpoint inhibitors are a basic science‐based, transformative new treatment for lung cancer

Miller, Alistair

doi:10.1111/resp.14437

Cited by 3 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a further paradigm shift, ICI are now used in early stage lung cancer that is amenable to surgical resection. 65 The landmark CheckMate 816 study randomized 358 patients with resectable stage IB-IIIA NSCLC to receive neoadjuvant nivolumab plus chemotherapy or chemotherapy alone. 66 The addition of nivolumab to chemotherapy resulted in a significantly longer event-free survival (31.6 vs. 20.8 months, p = 0.005) and higher percentage achieving pathologic complete response (24.0% vs. 2.2%, p < 0.001).…”

Section: Neoadjuvant and Adjuvant Ici Usementioning

confidence: 99%

“…In a further paradigm shift, ICI are now used in early stage lung cancer that is amenable to surgical resection 65 . The landmark CheckMate 816 study randomized 358 patients with resectable stage IB‐IIIA NSCLC to receive neoadjuvant nivolumab plus chemotherapy or chemotherapy alone 66 .…”

Section: Immune Checkpoint Inhibitors (Icis) In Early Stage Resectabl...mentioning

confidence: 99%

See 1 more Smart Citation

Contemporary Concise Review 2023: Advances in lung cancer and interventional pulmonology

Leong,

Steinfort

2024

Respirology

View full text Add to dashboard Cite

Summary of Key Points Eligibility criteria for lung cancer screening increasingly need to consider family history of lung cancer, as well as age and smoking status. Lung cancer screening will reveal a multitude of incidental findings, of variable clinical significance, and with a need for clear pathways of management. Pulmonary nodule sampling is enhanced by intra‐procedural imaging and cutting‐edge robotic technology. Systematic thoracic lymph node sampling has implications for treatment efficacy. Bronchoscopic ablative techniques are feasible for peripheral lung cancers. Bronchoscopic sampling continues to have a high yield for lung cancer molecular characterization. Immunotherapy indications have expanded to include early stage and resectable lung cancer.

show abstract

Section: Neoadjuvant and Adjuvant Ici Usementioning

confidence: 99%

Section: Immune Checkpoint Inhibitors (Icis) In Early Stage Resectabl...mentioning

confidence: 99%

Contemporary Concise Review 2023: Advances in lung cancer and interventional pulmonology

Leong,

Steinfort

2024

Respirology

View full text Add to dashboard Cite

show abstract

Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials

Xu,

Liang,

et al. 2023

Clinical Oncology

View full text Add to dashboard Cite